Following a full submission
AWMSG advice |
||
| Status: Recommended with restrictions | ||
Eculizumab (Soliris®) is recommended for restricted use within NHS Wales according to agreed guidelines for the treatment of paroxysmal nocturnal haemoglobinuria. |
||
|
||
Medicine details |
||
| Medicine name | eculizumab (Soliris®) | |
| Formulation | 300 mg concentrate for solution for infusion | |
| Reference number | 117 | |
| Indication | Treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH) |
|
| Company | Alexion Pharma UK Ltd | |
| BNF chapter | Nutrition & blood | |
| Assessment type | Full | |
| Status | Recommended with restrictions | |
| Advice number | 0509 | |
| NMG meeting date | 25/03/2009 | |
| AWMSG meeting date | 29/04/2009 | |
| Ratification by Welsh Government | 10/06/2009 | |
| Date of issue | 11/06/2009 | |
| Further information The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in December 2022. |
||